Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Acute Kidney Injury in Patients With NSTEMI

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Informed Consent as documented by a signature and date of the patient~2. Age 18-85 years~3. Acute NSTEMI as anticipated to be type 1 (expert opinion by the cardiologist before coronary angiography) and scheduled for urgent coronary angiography~4. Documented kidney disease existing for ≥3 months OR Two estimated glomerular filtration rate (eGFR) measurements of \<60ml/min/1.73m2 as calculated by the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) study equation and at least 6 hours apart OR eGFR of \<50 mL/min//1.73m2 as calculated by using the CKD-EPI study equation at presentation~5. At least one of the following risk factors for AKI: diabetes mellitus, age \>60 years, established cardiovascular disease, heart failure with reduced ejection fraction, anemia~Exclusion Criteria:~1. Contraindications to the class of drugs under study (C1 esterase inhibitors), e.g. known hypersensitivity or allergy to class of drugs or the IMP~2. History or suspicion of allergy to rabbits~3. Women who are pregnant or breast feeding~4. ST elevation myocardial infarction or unstable angina~5. Cardiogenic shock requiring mechanical support~6. Non-cardiac comorbidity with expected survival \<6 months~7. Acute urinary tract infection (e.g. cystitis, pyelonephritis).~8. Liver cirrhosis (any Child-Pugh score)~9. Dialysis or eGFR \<20 and \>59mL/min/1.73 m2 at baseline (d0)~10. Incapacity or inability to provide informed consent~11. Participation in another study with investigational drug within 30 days preceding, and during the present study~12. Previous enrolment into the current study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Conestat alfa 50 U/kg - Placebo (Type: PLACEBO_COMPARATOR): 50 U/kg conestat alfa pre-angiography and placebo 3 hours after the first dose
- Conestat alfa 50 U/kg - Conestat alfa 50 U/kg (Type: ACTIVE_COMPARATOR): 50 U/kg conestat alfa pre-angiography and 3 hours after the first dose
- Conestat alfa 100 U/kg - Conestat alfa 50 U/kg (Type: ACTIVE_COMPARATOR): 100 U/kg conestat alfa pre-angiography and 50 U/kg conestat alfa 3 hours after the first dose
- Placebo - Placebo (Type: PLACEBO_COMPARATOR): Placebo pre-angiography and 3 hours after the first dose

Based on this trial design, predict the completion outcome and termination type (if applicable).